EMA Explains How To Comply With Future EudraVigilance Reporting Requirements
This article was originally published in SRA
The European Medicines Agency has issued a document explaining the changes that drug companies will need to make to their internal processes in the near future to allow them to carry out various pharmacovigilance-related tasks, such as reporting of drug side-effects and conducting signal management, when the EudraVigilance database is updated in 20171,2.
You may also be interested in...
The European Medicines Agency is asking drug companies and EU national competent authorities to prepare for the late November launch of the new EU pharmacovigilance database, which will have enhanced functionalities for reporting and analysing suspected adverse reactions.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.